SB-242235, a selective inhibitor of p38 mitogen-activated protein kinase. I: Preclinical pharmacokinetics

Xenobiotica

Volumn 32, Issue 3, 2002, Pages 221-233

  Ward, K W ^a   Proksch, J W ^a   Salyers, K L ^b   Azzarano, L M ^a   Morgan, J A ^a   Roethke, T J ^a   McSurdy Freed, J E ^a   Levy, M A ^c   Smith, B R ^a  

^a Preclin Drug Discovery Cardiovasc Urogenitary and Oncol Ctr for Excellence in Drug Discovery ^*  (United States)

^b Preclinical Drug Discovery Antimicrobial and Host Defence Centre for Excellence in Drug Discovery   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 PIPERIDINYL) 4 (4 FLUOROPHENYL) 5 (2 METHOXY 4 PYRIMIDINYL)MIDAZOLE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; SB 242235; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; ENZYME ACTIVATION; INFLAMMATORY DISEASE; MALE; MONKEY; NONHUMAN; PLASMA CLEARANCE; RAT; SPECIES DIFFERENCE;

ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BLOOD PROTEINS; DIFFUSION; DOGS; ENZYME INHIBITORS; HALF-LIFE; HUMANS; IMIDAZOLES; MACACA FASCICULARIS; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN BINDING; PYRIDINES; RATS; SPECIES SPECIFICITY;

ANIMALIA; CANIS FAMILIARIS; RODENTIA;

EID: 0036202825     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/00498250110100720     Document Type: Article

References (20)

1. Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced disease
2. Pharmacokinetics: The dynamics of drug absorption, distribution, and elimination
3. Drug interactions at the renal level: Implications for drug development
4. MAP kinase pathways
5. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1
6. Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of Hsp27
7. Suppression of ex vivo cytokine production by SB 242235, a selective inhibitor of p38 MAP kinase
8. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells
9. Red blood cells: A neglected compartment in pharmacokinetics and pharmacodynamics
10. Bicyclic imidazoles as a novel class of cytokine biosynthesis inhibitors
11. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis
12. Pharmacokinetics and metabolism of SK&F 86002 in male and female Sprague-Dawley rats
13. Methods of determining plasma and tissue binding of drugs
14. A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins
15. The MAP kinase family: New 'MAPs' for signal transduction pathways and novel targets for drug discovery
16. SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence
17. Evaluation of the use of accelerated infusions for the determination of pharmacokinetic linearity
18. SB-242235, a selective inhibitor of p38 mitogen-activated protein kinase. II. In vitro and in vivo metabolism studies and pharmacokinetic extrapolation to man
19. p38 mitogen-activated protein kinase negatively regulates the induction of Phase II drug-metabolizing enzymes that detoxify carcinogens